Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeCoMe-9
NCT06611436Phase 2Terminated
- Sponsor
- Be Biopharma
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of BE-101 in hemophilia B (HB) (4 arms), sponsored by Be Biopharma. Primary endpoint: Adverse events and Serious Adverse Events at 1 year. Started Dec 2024; status: terminated.
02
Drugs
BE-101
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT06611436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611436.